Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
β Scribed by Tammy F Chu; Maria A Rupnick; Risto Kerkela; Susan M Dallabrida; David Zurakowski; Lisa Nguyen; Kathleen Woulfe; Elke Pravda; Flavia Cassiola; Jayesh Desai; Suzanne George; Jeffrey A Morgan; David M Harris; Nesreen S Ismail; Jey-Hsin Chen; Frederick J Schoen; Annick D Van den Abbeele; George D Demetri; Thomas Force; Ming Hui Chen
- Book ID
- 117302229
- Publisher
- The Lancet
- Year
- 2007
- Tongue
- English
- Weight
- 601 KB
- Volume
- 370
- Category
- Article
- ISSN
- 0140-6736
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. Sunitinib malate is a novel multitargeted receptor tyrosine kinase inhibitor with established efficacy in the treatment of metastatic renal cell carcinoma and imatinibβresistant gastrointestinal stromal tumor. This report describes the development of heart failure in can